Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 2 of 8012345...102030...Last »

Lilly’s Cyramza meets main goal for gastric cancer

Eli Lilly & Co.’s Cyramza met the main study goal but failed to improve survival rates in a late-stage trial for gastric cancer.

Read More »

Breast cancer drug superior to chemo in study

Pfizer’s talazoparib for advanced breast cancer was demonstrated to be superior to chemotherapy in a late-stage study.

Read More »

Roche study: Cancer ‘Velcro’ halts T-cell attack

Roche scientists may have discovered why some tumors resist new immunotherapy drugs as well as a possible means of turning the tables to incite a T-cell attack.

Read More »

Sage’s depression drug succeeds in study

Sage Therapeutics Inc.’s drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

Read More »

Sanofi’s Toujeo met main objective in study

Sanofi’s Toujeo met the primary study objective in the first large head-to-head clinical trial, called BRIGHT study, comparing Toujeo with insulin degludec.

Read More »

Sanofi ends development of C. difficile vaccine

Sanofi SA ended development of an experimental vaccine for Clostridium difficile infection.

Read More »

Bristol-Myers’ Lung Cancer Opdivo Trial Stopped Early for Superior Overall Survival

Bristol-Myers Squibb announced that the company’s Phase III trial pitting Opdivo against chemotherapy drug docetaxel in treating certain lung cancer patients was stopped early after meeting key endpoints.

Read More »

Aimovig Halves Length of Migraine Attacks in Study

Amgen unveiled results from a late-stage study that shows the company’s Phase III drug Aimovig reduced monthly migraine attacks in half.

Read More »

Merck KGaA, Pfizer’s immunotherapy fails in gastric cancer trial

Germany’s Merck KGaA suffered a setback in the development of the company’s key cancer immunotherapy Bavencio, which failed in a trial to prolong lives in gastric cancer patients when compared with standard chemotherapy.

Read More »

Ardelyx to Ditch Phase III Hyperkalemia Drug

Ardelyx decided to shutter development of RDX7675 – an experimental medicine for hyperkalemia – including the onset-of-action trial and Phase III studies.

Read More »

Cytokinetics abandons ALS drug after failed trial, shares tank

Cytokinetics Inc. will stop developing one of its treatments for ALS – which afflicts Stephen Hawking – after the drug failed in a late-stage trial, sending the company’s shares tumbling about 35 percent.

Read More »

Roche stock up $12 billion on cancer, hemophilia trials

Roche shares were lifted by two clinical trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker is counting on to offset shrinking revenue from older medicines.

Read More »

Argos Reports Positive Kidney Cancer Data

Argos Therapeutics announced positive interim data for the company’s kidney cancer drug Rocapuldencel-T from a Phase III clinical trial.

Read More »

Nanotech, gene editing used to edit cholesterol gene: U.S. study

U.S. researchers have used nanotechnology plus the powerful CRISPR-Cas9 gene editing tool to turn off a key cholesterol-related gene in mouse liver cells.

Read More »

Otonomy Lead Drug Succeeds in Late-Stage Study

Otonomy announced the success of its AVERTS-2 Phase III clinical trial of Otividex in patients with Meniere’s disease.

Read More »

Sage soars as postpartum depression drug moves closer to approval

Sage Therapeutics Inc.’s postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.

Read More »

Stelara shows promise against lupus in study

J&J’s blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a mid-stage clinical trial.

Read More »

Amgen, Novartis Rev Up for New Alzheimer’s Study

Amgen and Novartis announced that they expanded their collaboration with the Banner Alzheimer’s Institute to launch a new clinical trial in Alzheimer’s.

Read More »

Alnylam drug reverses rare fatal disease progress

More than half of patients with a rare genetic disorder experienced significant improvement after being treated with an Alnylam drug that uses gene silencing technology.

Read More »

AstraZeneca Asthma Drug Fails Late-Stage Trials

AstraZeneca and its MedImmune division announced two Phase III trials of tralokinumab for severe, uncontrolled asthma failed to meet their primary endpoints.

Read More »

Page 2 of 8012345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2017 Focus: Ad Agency Roundtable and more!


Ad Right Bottom

Main Navigation